Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.2.3.13NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.3.9NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.3.9NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.3.9NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.10.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.10.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.10.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.56NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.56NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.56NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.29NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.29NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.29NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.10NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.10NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.10NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.112NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.112NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.112NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.123NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.123NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.123NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.143NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.143NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.143NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.29NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.29NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.29NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBB.1.48NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.48NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBB.1.48NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.46.6.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.46.6.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.46.6.1 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.112.1 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.112.1 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.112.1 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.360NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.360NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.360NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.49NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.49NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-1906.48Singapore
B.1.177.49NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.347NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.347NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.347NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.195NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.195NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.195NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.321NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used